Tumor necrosis factor-α inhibitors for the treatment of four cases of hidradenitis suppurativa
- VernacularTitle:肿瘤坏死因子α抑制剂治疗化脓性汗腺炎四例
- Author:
Bei SHI
1
;
Guannan ZHU
;
Meng FU
Author Information
- Keywords: Hidradenitis suppurativa; Biological agents; Treatment; Infliximab; Adalimumab
- From: Chinese Journal of Dermatology 2021;54(10):901-903
- CountryChina
- Language:Chinese
- Abstract: Four male cases of hidradenitis suppurativa (Hurley stage Ⅱ/Ⅲ) aged 20 - 45 years were collected from Department of Dermatology, Xijing Hospital, the Fourth Military Medical University from August 2017 to December 2019. All the patients presented with sinuses, abscesses and scars on the buttocks, axillary and inguinal regions, and showed a poor response to previous treatment with antibiotics, glucocorticoids, retinoids, traditional Chinese medicine, etc. The patients were treated with intravenous drips of infliximab at a dose of 5 mg/kg at weeks 0, 2 and 6, followed by an every-9-week treatment regimen, or with subcutaneous injection of adalimumab at a dose of 80 mg at weeks 0 and 2, followed by an every-3-week regimen at a dose of 40 mg. Two patients experienced infusion reactions after intravenous drips of infliximab, and then were switched to adalimumab. Three of these patients achieved hidradenitis suppurativa clinical response, whereas 1 showed no response.
